siRNA-based strategies to combat drug resistance in gastric cancer.
Cancer therapy
Chemotherapy
Drug resistance
Gastric cancer
siRNA
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
21 Oct 2024
21 Oct 2024
Historique:
received:
17
08
2024
accepted:
27
09
2024
medline:
21
10
2024
pubmed:
21
10
2024
entrez:
20
10
2024
Statut:
epublish
Résumé
Chemotherapy is a key treatment option for gastric cancer, but over 50% of patients develop either inherent or acquired resistance to these drugs, resulting in a 5-year survival rate of only about 20%. The primary treatment for advanced gastric cancer typically involves chemotherapy based on platinum or fluorouracil. Several factors can contribute to platinum resistance, including decreased drug uptake, increased drug efflux or metabolism, enhanced DNA repair, activation of pro-survival pathways, and inhibition of pro-apoptotic pathways. In recent years, there has been significant progress in biology aimed at finding innovative and more effective methods to overcome chemotherapy resistance. Small interfering RNAs (siRNAs) have emerged as a significant advancement in gene expression regulation, showing promise in enhancing the sensitivity of gastric cancer cells to chemotherapy drugs. However, siRNA therapies still face major challenges, particularly in terms of stability and efficient delivery in vivo. This article discusses the advances in siRNA therapy and its potential role in overcoming resistance to chemotherapeutic drugs such as cisplatin, 5-FU, doxorubicin, and paclitaxel in the treatment of gastric cancer.
Identifiants
pubmed: 39428440
doi: 10.1007/s12032-024-02528-w
pii: 10.1007/s12032-024-02528-w
doi:
Substances chimiques
RNA, Small Interfering
0
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
293Subventions
Organisme : King Khalid University
ID : R.G.P.2/369/44
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Kamrani A, Nasiri H, Hassanzadeh A, Ahmadian Heris J, Mohammadinasab R, Sadeghvand S, Sadeghi M, et al. New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses. Cell Commun Signal. 2024;22(1):56.
pubmed: 38243252
pmcid: 10799490
doi: 10.1186/s12964-023-01430-8
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.
pubmed: 23485231
doi: 10.1016/j.ejca.2012.12.027
Gao W, Bigham A, Ghomi M, Zarrabi A, Rabiee N, Saeb MR, Nuri Ertas Y, et al. Micelle-engineered nanoplatforms for precision oncology. Chem Eng J. 2024;495: 153438.
doi: 10.1016/j.cej.2024.153438
Rezapour S, Hosseinzadeh E, Marofi F, Hassanzadeh A. Epigenetic-based therapy for colorectal cancer: prospect and involved mechanisms. J Cell Physiol. 2019;234(11):19366–83.
pubmed: 31020647
doi: 10.1002/jcp.28658
Lu Q, Kou D, Lou S, Ashrafizadeh M, Aref AR, Canadas I, Tian Y, et al. Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy. J Hematol Oncol. 2024;17(1):16.
pubmed: 38566199
pmcid: 10986145
doi: 10.1186/s13045-024-01535-8
Wang Z, Pang S, Liu X, Dong Z, Tian Y, Ashrafizadeh M, Rabiee N, et al. Chitosan- and hyaluronic acid-based nanoarchitectures in phototherapy: combination cancer chemotherapy, immunotherapy and gene therapy. Int J Biol Macromol. 2024;273: 132579.
pubmed: 38795895
doi: 10.1016/j.ijbiomac.2024.132579
Dai J, Ashrafizadeh M, Aref AR, Sethi G, Ertas YN. Peptide-functionalized, -assembled and -loaded nanoparticles in cancer therapy. Drug Discov Today. 2024;29(7): 103981.
pubmed: 38614161
doi: 10.1016/j.drudis.2024.103981
Yan H, Chen W, Ge K, Mao X, Li X, Liu W, Wu J, et al. Value of plasma methylated SFRP2 in prognosis of gastric cancer. Dig Dis Sci. 2021;66:3854–61.
pubmed: 33216241
doi: 10.1007/s10620-020-06710-8
Zhang X, Huang T, Li Y, Qiu H. Upregulation of THBS1 is related to immunity and chemotherapy resistance in gastric cancer. Int J Gen Med. 2021;1:4945–57.
doi: 10.2147/IJGM.S329208
Wei L, Sun J, Zhang N, Zheng Y, Wang X, Lv L, Liu J, et al. Noncoding RNAs in gastric cancer: implications for drug resistance. Mol Cancer. 2020;19(1):62.
pubmed: 32192494
pmcid: 7081551
doi: 10.1186/s12943-020-01185-7
Zhou Y, Chen Y, Shi Y, Wu L, Tan Y, Li T, Chen Y, et al. FAM117B promotes gastric cancer growth and drug resistance by targeting the KEAP1/NRF2 signaling pathway. J Clin Invest. 2023;133(3)
Hashemi M, Aparviz R, Beickzade M, Paskeh MDA, Kheirabad SK, Koohpar ZK, Moravej A, et al. Advances in RNAi therapies for gastric cancer: Targeting drug resistance and nanoscale delivery. Biomed Pharmacother. 2023;169: 115927.
pubmed: 38006616
doi: 10.1016/j.biopha.2023.115927
Hu X, Ma Z, Xu B, Li S, Yao Z, Liang B, Wang J, et al. Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer. Cancer Commun (Lond). 2023;43(8):909–37.
pubmed: 37434399
doi: 10.1002/cac2.12459
Liu J, Yuan Q, Guo H, Guan H, Hong Z, Shang D. Deciphering drug resistance in gastric cancer: Potential mechanisms and future perspectives. Biomed Pharmacother. 2024;173: 116310.
pubmed: 38394851
doi: 10.1016/j.biopha.2024.116310
Ouyang S, Li H, Lou L, Huang Q, Zhang Z, Mo J, Li M, et al. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biol. 2022;52: 102317.
pubmed: 35483272
pmcid: 9108091
doi: 10.1016/j.redox.2022.102317
Wang S, Chen W, Yu H, Song Z, Li Q, Shen X, Wu Y, et al. lncRNA ROR promotes gastric cancer drug resistance. Cancer Control. 2020;27(1):1073274820904694.
pubmed: 32019330
pmcid: 7003177
doi: 10.1177/1073274820904694
Che G, Yin J, Wang W, Luo Y, Chen Y, Yu X, Wang H, et al. Circumventing drug resistance in gastric cancer: a spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics. Drug Resist Updat. 2024;74: 101080.
pubmed: 38579635
doi: 10.1016/j.drup.2024.101080
Yang W, Ma J, Zhou W, Cao B, Zhou X, Yang Z, Zhang H, et al. Molecular mechanisms and theranostic potential of miRNAs in drug resistance of gastric cancer. Expert Opin Ther Targets. 2017;21(11):1063–75.
pubmed: 28994330
doi: 10.1080/14728222.2017.1389900
Zheng Y, Li Z, Wang Y, Chen W, Lin Y, Guo J, Ye G. CircRNA: A new class of targets for gastric cancer drug resistance therapy. Pathol Oncol Res. 2023;29:1611033.
pubmed: 37065861
pmcid: 10097900
doi: 10.3389/pore.2023.1611033
Wang X, Zhang J, Cao G, Hua J, Shan G, Lin W. Emerging roles of circular RNAs in gastric cancer metastasis and drug resistance. J Exp Clin Cancer Res. 2022;41(1):218.
pubmed: 35821160
pmcid: 9277821
doi: 10.1186/s13046-022-02432-z
Lu Y, Jin Z, Hou J, Wu X, Yu Z, Yao L, Pan T, et al. Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer. Matrix Biol. 2023;115:1–15.
pubmed: 36423735
doi: 10.1016/j.matbio.2022.11.005
Zhang Q, Zhang H, Ning T, Liu D, Deng T, Liu R, Bai M, et al. Exosome-delivered c-Met siRNA could reverse chemoresistance to cisplatin in gastric cancer. Int J Nanomed. 2020;15:2323–35.
doi: 10.2147/IJN.S231214
Zhang X, Wang S, Wang H, Cao J, Huang X, Chen Z, Xu P, et al. Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway. Mol Cancer. 2019;18(1):20.
pubmed: 30717751
pmcid: 6360801
doi: 10.1186/s12943-018-0935-5
Yao H, Sun L, Li J, Zhou X, Li R, Shao R, Zhang Y, et al. A novel therapeutic siRNA nanoparticle designed for dual-targeting CD44 and Gli1 of gastric cancer stem cells. Int J Nanomed. 2020;15:7013–34.
doi: 10.2147/IJN.S260163
Wenying Z, Zhaoning J, Zhimin Y, Dongyun C, Lili S. Survivin siRNA inhibits gastric cancer in nude mice. Cell Biochem Biophys. 2012;62(2):337–41.
pubmed: 22052003
doi: 10.1007/s12013-011-9315-0
Reza MN, Mahmud S, Ferdous N, Ahammad I, Hossain MU, Al Amin M, Mohiuddin AKM. Gene silencing of Helicobacter pylori through newly designed siRNA convenes the treatment of gastric cancer. Cancer Med. 2023;12(24):22407–19.
pubmed: 38037736
pmcid: 10757103
doi: 10.1002/cam4.6772
Sun Y, Guo BF, Xu LB, Zhong JT, Liu ZW, Liang H, Wen NY, et al. Stat3-siRNA inhibits the growth of gastric cancer in vitro and in vivo. Cell Biochem Funct. 2015;33(7):495–502.
pubmed: 26486443
doi: 10.1002/cbf.3148
Wang XT, Xie YB, Xiao Q. siRNA targeting of Cdx2 inhibits growth of human gastric cancer MGC-803 cells. World J Gastroenterol. 2012;18(16):1903–14.
pubmed: 22563170
pmcid: 3337565
doi: 10.3748/wjg.v18.i16.1903
Fan L, Tan B, Li Y, Zhao Q, Liu Y, Wang D, Zhang Z. Silencing of ZNF139-siRNA induces apoptosis in human gastric cancer cell line BGC823. Int J Clin Exp Pathol. 2015;8(10):12428–36.
pubmed: 26722429
pmcid: 4680374
Fonseca Cabral G, Azevedo Dos Santos Pinheiro J, Vidal AF, Santos S, Ribeiro-Dos-Santos Â. piRNAs in Gastric Cancer: A New Approach Towards Translational Research. Int J Mol Sci. 2020;21(6)
Mirzaei S, Mahabady MK, Zabolian A, Abbaspour A, Fallahzadeh P, Noori M, Hashemi F, et al. Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: Current status with an emphasis on delivery systems. Life Sci. 2021;275: 119368.
pubmed: 33741417
doi: 10.1016/j.lfs.2021.119368
Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Hushmandi K, Rahmanian V, Entezari M, et al. Employing siRNA tool and its delivery platforms in suppressing cisplatin resistance: approaching to a new era of cancer chemotherapy. Life Sci. 2021;277: 119430.
pubmed: 33789144
doi: 10.1016/j.lfs.2021.119430
Yang C, Ma D, Lu L, Yang X, Xi Z. Synthesis of KUE-siRNA conjugates for prostate cancer cell-targeted gene silencing. ChemBioChem. 2021;22(19):2888–95.
pubmed: 34263529
doi: 10.1002/cbic.202100243
Zhang P, An K, Duan X, Xu H, Li F, Xu F. Recent advances in siRNA delivery for cancer therapy using smart nanocarriers. Drug Discov Today. 2018;23(4):900–11.
pubmed: 29373841
doi: 10.1016/j.drudis.2018.01.042
Hassanzadeh A, Rahman HS, Markov A, Endjun JJ, Zekiy AO, Chartrand MS, Beheshtkhoo N, et al. Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities. 2021;12(1):297
Hassanzadeh A, Shamlou S, Yousefi N, Nikoo M, Verdi J. Genetically-modified stem cell in regenerative medicine and cancer therapy; A new era. Curr Gene Ther. 2022;22(1):23–39.
pubmed: 34238158
Marofi F, Abdul-Rasheed OF, Rahman HS, Budi HS, Jalil AT, Yumashev AV, Hassanzadeh A, et al. CAR-NK cell in cancer immunotherapy; A promising frontier. Cancer Sci. 2021;112(9):3427–36.
pubmed: 34050690
pmcid: 8409419
doi: 10.1111/cas.14993
Subhan MA, Torchilin VP. Efficient nanocarriers of siRNA therapeutics for cancer treatment. Transl Res. 2019;214:62–91.
pubmed: 31369717
doi: 10.1016/j.trsl.2019.07.006
Xiao B, Ma L, Merlin D. Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy. Expert Opin Drug Deliv. 2017;14(1):65–73.
pubmed: 27337289
doi: 10.1080/17425247.2016.1205583
Yan Y, Wang CH, Cui SH, Zhai L, Sun J, Liu XY, Chen X, et al. Enhanced cancer therapeutic efficiency of NO combined with siRNA by caspase-3 responsive polymers. J Control Release. 2021;339:506–20.
pubmed: 34655677
doi: 10.1016/j.jconrel.2021.10.012
Shi Z, Yang Y, Guo Z, Feng S, Wan Y. A cathepsin B/GSH dual-responsive fluorinated peptide for effective siRNA delivery to cancer cells. Bioorg Chem. 2023;135: 106485.
pubmed: 36963370
doi: 10.1016/j.bioorg.2023.106485
Singh A, Trivedi P, Jain NK. Advances in siRNA delivery in cancer therapy. Artif Cells Nanomed Biotechnol. 2018;46(2):274–83.
pubmed: 28423924
doi: 10.1080/21691401.2017.1307210
Subhan MA, Attia SA, Torchilin VP. Advances in siRNA delivery strategies for the treatment of MDR cancer. Life Sci. 2021;274: 119337.
pubmed: 33713664
doi: 10.1016/j.lfs.2021.119337
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836):494–8.
pubmed: 11373684
doi: 10.1038/35078107
Zhang MM, Bahal R, Rasmussen TP, Manautou JE, Zhong XB. The growth of siRNA-based therapeutics: updated clinical studies. Biochem Pharmacol. 2021;189: 114432.
pubmed: 33513339
doi: 10.1016/j.bcp.2021.114432
Mishra DK, Balekar N, Mishra PK. Nanoengineered strategies for siRNA delivery: from target assessment to cancer therapeutic efficacy. Drug Deliv Transl Res. 2017;7(2):346–58.
pubmed: 28050890
doi: 10.1007/s13346-016-0352-5
Mousazadeh H, Pilehvar-Soltanahmadi Y, Dadashpour M, Zarghami N. Cyclodextrin based natural nanostructured carbohydrate polymers as effective non-viral siRNA delivery systems for cancer gene therapy. J Control Release. 2021;330:1046–70.
pubmed: 33188829
doi: 10.1016/j.jconrel.2020.11.011
Ngamcherdtrakul W, Yantasee W. siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion. Transl Res. 2019;214:105–20.
pubmed: 31487500
pmcid: 6848785
doi: 10.1016/j.trsl.2019.08.005
Friedrich M, Aigner A. Therapeutic siRNA: state-of-the-art and future perspectives. BioDrugs. 2022;36(5):549–71.
pubmed: 35997897
pmcid: 9396607
doi: 10.1007/s40259-022-00549-3
Mangala LS, Rodriguez-Aguayo C, Bayraktar E, Jennings NB, Lopez-Berestein G, Sood AK. Assessment of in vivo siRNA delivery in cancer mouse models. Methods Mol Biol. 2021;2372:157–68.
pubmed: 34417750
doi: 10.1007/978-1-0716-1697-0_14
Mehanna MM, Abla KK. siRNA nanohybrid systems: false hope or feasible answer in cancer management. Ther Deliv. 2022;13(2):109–33.
pubmed: 35105155
doi: 10.4155/tde-2021-0068
Ashrafizadeh M, Delfi M, Hashemi F, Zabolian A, Saleki H, Bagherian M, Azami N, et al. Biomedical application of chitosan-based nanoscale delivery systems: potential usefulness in siRNA delivery for cancer therapy. Carbohydr Polym. 2021;260: 117809.
pubmed: 33712155
doi: 10.1016/j.carbpol.2021.117809
Lee SJ, Kim MJ, Kwon IC, Roberts TM. Delivery strategies and potential targets for siRNA in major cancer types. Adv Drug Deliv Rev. 2016;104:2–15.
pubmed: 27259398
pmcid: 4958528
doi: 10.1016/j.addr.2016.05.010
Sharma A, Kumar P, Ambasta RK. Cancer fighting SiRNA-RRM2 loaded nanorobots. Pharm Nanotechnol. 2020;8(2):79–90.
pubmed: 32003677
doi: 10.2174/2211738508666200128120142
Wang M, Wang J, Li B, Meng L, Tian Z. Recent advances in mechanism-based chemotherapy drug-siRNA pairs in co-delivery systems for cancer: a review. Colloids Surf B Biointerfaces. 2017;157:297–308.
pubmed: 28601758
doi: 10.1016/j.colsurfb.2017.06.002
Isazadeh H, Oruji F, Shabani S, Behroozi J, Nasiri H, Isazadeh A, Akbari M. Advances in siRNA delivery approaches in cancer therapy: challenges and opportunities. Mol Biol Rep. 2023;50(11):9529–43.
pubmed: 37741808
doi: 10.1007/s11033-023-08749-y
Foster DJ, Brown CR, Shaikh S, Trapp C, Schlegel MK, Qian K, Sehgal A, et al. Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates. Mol Ther. 2018;26(3):708–17.
pubmed: 29456020
pmcid: 5910670
doi: 10.1016/j.ymthe.2017.12.021
Bholakant R, Qian H, Zhang J, Huang X, Huang D, Feijen J, Zhong Y, et al. Recent advances of polycationic siRNA vectors for cancer therapy. Biomacromol. 2020;21(8):2966–82.
doi: 10.1021/acs.biomac.0c00438
Barati M, Mirzavi F, Atabaki M, Bibak B, Mohammadi M, Jaafari MR. A review of PD-1/PD-L1 siRNA delivery systems in immune T cells and cancer cells. Int Immunopharmacol. 2022;111: 109022.
pubmed: 35987146
doi: 10.1016/j.intimp.2022.109022
Alshaer W, Zureigat H, Al Karaki A, Al-Kadash A, Gharaibeh L, Hatmal MM, Aljabali AAA, et al. siRNA: mechanism of action, challenges, and therapeutic approaches. Eur J Pharmacol. 2021;905: 174178.
pubmed: 34044011
doi: 10.1016/j.ejphar.2021.174178
Radia A-M, Yaser A-M, Ma X, Zhang J, Yang C, Dong Q, Rong P, et al. Specific siRNA targeting receptor for advanced glycation end products (RAGE) decreases proliferation in human breast cancer cell lines. Int J Mol Sci. 2013;14(4):7959–78.
pubmed: 23579957
pmcid: 3645726
doi: 10.3390/ijms14047959
Chen Y, Huang Y, Li Q, Luo Z, Zhang Z, Huang H, Sun J, et al. Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy. Nat Nanotechnol. 2023;18(2):193–204.
pubmed: 36424448
doi: 10.1038/s41565-022-01266-2
Dhanya CR, Mary AS, Madhavan M. Aptamer-siRNA chimeras: Promising tools for targeting HER2 signaling in cancer. Chem Biol Drug Des. 2023;101(5):1162–80.
pubmed: 36099164
doi: 10.1111/cbdd.14143
Guo Y, Zhang Q, Zhu Q, Gao J, Zhu X, Yu H, Li Y, et al. Copackaging photosensitizer and PD-L1 siRNA in a nucleic acid nanogel for synergistic cancer photoimmunotherapy. Sci Adv. 2022;8(16):eabn2941.
pubmed: 35442728
pmcid: 9020667
doi: 10.1126/sciadv.abn2941
Paskeh MDA, Saebfar H, Mahabady MK, Orouei S, Hushmandi K, Entezari M, Hashemi M, et al. Overcoming doxorubicin resistance in cancer: siRNA-loaded nanoarchitectures for cancer gene therapy. Life Sci. 2022;298: 120463.
pubmed: 35259354
doi: 10.1016/j.lfs.2022.120463
Sun H-W, Tong S-L, He J, Wang Q, Zou L, Ma S-J, Tan H-Y, et al. RhoA and RhoC-siRNA inhibit the proliferation and invasiveness activity of human gastric carcinoma by Rho/PI3K/Akt pathway. World J Gastroenterol. 2007;13(25):3517.
pubmed: 17659701
pmcid: 4146790
doi: 10.3748/wjg.v13.i25.3517
Li R, Chen W-C, Pang X-Q, Tian W-Y, Wang W-P, Zhang X-GJ. Combined effect of sCD40L and PI3K siRNA on transplanted tumours growth and microenvironment in nude mice with gastric cancer. Mol Biol Rep. 2012;39:8755–61.
pubmed: 22736104
doi: 10.1007/s11033-012-1736-3
Hao J, Gu Q, Liu B, Li J, Chen X, Ji Y, Zhu Z, et al. Inhibition of the proliferation of human gastric cancer cells SGC-7901in vitroandin vivousing Bcl-2 siRNA. Chin Med J. 2007;120(23):2105–11.
pubmed: 18167184
doi: 10.1097/00029330-200712010-00008
Sun L, Zhang Y, Lou J. ARHGAP9 siRNA inhibits gastric cancer cell proliferation and EMT via inactivating Akt, p38 signaling and inhibiting MMP2 and MMP9. Int J Clin Exp Pathol. 2017;10(12):11979.
pubmed: 31966562
pmcid: 6966049
Tan B, Li Y, Zhao Q, Fan L, Wang D, Liu Y. Inhibition of gastric cancer cell growth and invasion through siRNA-mediated knockdown of guanine nucleotide exchange factor Vav3. Tumor Biol. 2014;35:1481–8.
doi: 10.1007/s13277-013-1204-2
Cai L, Ma X, Huang Y, Zou Y, Chen X. Aberrant histone methylation and the effect of Suv39H1 siRNA on gastric carcinoma. Oncol Rep. 2014;31(6):2593–600.
pubmed: 24737085
doi: 10.3892/or.2014.3135
Yuan H-F, Li Y, Tan B-B, Zhao Q, Fan L-Q, An Z-J. Inhibitory effect of siRNA-Annexin A7 on growth, migration, and invasion in BGC823 cells and gastric cancer xenograftsin nude mice. Int J Clin Exp Pathol. 2020;13(2):122.
pubmed: 32211092
pmcid: 7061786
Wang H, Liu M, Zeng X, Zheng Y, Wang Y, Zhou Y. Cell death affecting the progression of gastric cancer. Cell Death Discov. 2022;8(1):377.
pubmed: 36038533
pmcid: 9424204
doi: 10.1038/s41420-022-01161-8
Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. Cell Res. 2019;29(5):347–64.
pubmed: 30948788
pmcid: 6796845
doi: 10.1038/s41422-019-0164-5
Tong X, Tang R, Xiao M, Xu J, Wang W, Zhang B, Liu J, et al. Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. J hematol oncol. 2022;15(1):174.
pubmed: 36482419
pmcid: 9733270
doi: 10.1186/s13045-022-01392-3
Ye X-L, Zhao Y-R, Weng G-B, Chen Y-C, Wei X-N, Shao J-P, Ji H. IL-33-induced JNK pathway activation confers gastric cancer chemotherapy resistance. Oncol Rep. 2015;33(6):2746–52.
pubmed: 25846650
doi: 10.3892/or.2015.3898
Zhao J, Fu X, Chen H, Min L, Sun J, Yin J, Guo J, et al. G3BP1 interacts with YWHAZ to regulate chemoresistance and predict adjuvant chemotherapy benefit in gastric cancer. Br J Cancer. 2021;124(2):425–36.
pubmed: 32989225
doi: 10.1038/s41416-020-01067-1
Li X, He S, Ma B. Autophagy and autophagy-related proteins in cancer. Mol Cancer. 2020;19(1):12.
pubmed: 31969156
pmcid: 6975070
doi: 10.1186/s12943-020-1138-4
Li Y-J, Lei Y-H, Yao N, Wang C-R, Hu N, Ye W-C, Zhang D-M, et al. Autophagy and multidrug resistance in cancer. Chin J Cancer. 2017;36:1–10.
doi: 10.1186/s40880-017-0219-2
Xiao F, Ouyang B, Zou J, Yang Y, Yi L, Yan H. Trim14 promotes autophagy and chemotherapy resistance of gastric cancer cells by regulating AMPK/mTOR pathway. Drug Dev Res. 2020;81(5):544–50.
pubmed: 32096264
doi: 10.1002/ddr.21650
Ren J, Hu Z, Niu G, Xia J, Wang X, Hong R, Gu J, et al. Annexin A1 induces oxaliplatin resistance of gastric cancer through autophagy by targeting PI3K/AKT/mTOR. FASEB J. 2023;37(3):e22790.
pubmed: 36786694
doi: 10.1096/fj.202200400RR
Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):99–115.
pubmed: 30470818
doi: 10.1038/s41573-018-0004-1
Gu J, Li X, Zhao L, Yang Y, Xue C, Gao Y, Li J, et al. The role of PKM2 nuclear translocation in the constant activation of the NF-κB signaling pathway in cancer-associated fibroblasts. Cell Death Dis. 2021;12(4):291.
pubmed: 33731686
pmcid: 7969736
doi: 10.1038/s41419-021-03579-x
Ham I-H, Wang L, Lee D, Woo J, Kim TH, Jeong HY, Oh HJ, et al. Curcumin inhibits the cancer-associated fibroblast-derived chemoresistance of gastric cancer through the suppression of the JAK/STAT3 signaling pathway. Int J Oncol. 2022;61(1):1–12.
doi: 10.3892/ijo.2022.5375
Van Overmeire E, Laoui D, Keirsse J, Van Ginderachter JA, Sarukhan A. Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues. Front Immunol. 2014;5:127.
pubmed: 24723924
pmcid: 3972476
Zheng P, Chen L, Yuan X, Luo Q, Liu Y, Xie G, Ma Y, et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J Exp Clin Cancer Res. 2017;36:1–13.
doi: 10.1186/s13046-017-0528-y
Peixoto P, Cartron P-F, Serandour AA, Hervouet E. From 1957 to nowadays: a brief history of epigenetics. Int J Mol Sci. 2020;21(20):7571.
pubmed: 33066397
pmcid: 7588895
doi: 10.3390/ijms21207571
Al-Imam MJ, Hussein UA-R, Sead FF, Faqri AMA, Mekkey SM, Almashhadani HA. The interactions between DNA methylation machinery and long non-coding RNAs in tumor progression and drug resistance. DNA Repair. 2023;128:1035.
doi: 10.1016/j.dnarep.2023.103526
Skinner KT, Palkar AM, Hong AL. Genetics of ABCB1 in cancer. Cancers. 2023;15(17):4236.
pubmed: 37686513
pmcid: 10487083
doi: 10.3390/cancers15174236
Choi SJ, Jung SW, Huh S, Chung Y-S, Cho H, Kang HJ. Alteration of DNA methylation in gastric cancer with chemotherapy. J Microbiol Biotechnol. 2017;27(8):1367–78.
pubmed: 28621113
doi: 10.4014/jmb.1704.04035
Ribatti D. Epithelial-mesenchymal transition in morphogenesis, cancer progression and angiogenesis. Exp Cell Res. 2017;353(1):1–5.
pubmed: 28257786
doi: 10.1016/j.yexcr.2017.02.041
Pan G, Liu Y, Shang L, Zhou F, Yang S. EMT-associated microRNAs and their roles in cancer stemness and drug resistance. Cancer Commun. 2021;41(3):199–217.
doi: 10.1002/cac2.12138
Mittal V. Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol Mech Dis. 2018;13(1):395–412.
doi: 10.1146/annurev-pathol-020117-043854
Loh C-Y, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP, et al. The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells. 2019;8(10):1118.
pubmed: 31547193
pmcid: 6830116
doi: 10.3390/cells8101118
Li B, Huang Q, Wei G-H. The role of HOX transcription factors in cancer predisposition and progression. Cancers. 2019;11(4):528.
pubmed: 31013831
pmcid: 6520925
doi: 10.3390/cancers11040528
Song C, Zhou C. HOXA10 mediates epithelial-mesenchymal transition to promote gastric cancer metastasis partly via modulation of TGFB2/Smad/METTL3 signaling axis. J Exp Clin Cancer Res. 2021;40:1–16.
doi: 10.1186/s13046-021-01859-0
Xu J, Liu D, Niu H, Zhu G, Xu Y, Ye D, Li J, et al. Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer. J Exp Clin Cancer Res. 2017;36:1–14.
doi: 10.1186/s13046-016-0487-8
Kumar S, Kumar A, Shah PP, Rai SN, Panguluri SK, Kakar SS. MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res. 2011;4(1):17.
pubmed: 21939554
pmcid: 3205057
doi: 10.1186/1757-2215-4-17
Monneret C. Platinum anticancer drugs. From serendipity to rational design. Ann Pharm Fr. 2011;69(6):286–95.
pubmed: 22115131
doi: 10.1016/j.pharma.2011.10.001
Ye MX, Zhao YL, Li Y, Miao Q, Li ZK, Ren XL, Song LQ, et al. Curcumin reverses cis-platin resistance and promotes human lung adenocarcinoma A549/DDP cell apoptosis through HIF-1α and caspase-3 mechanisms. Phytomedicine. 2012;19(8–9):779–87.
pubmed: 22483553
doi: 10.1016/j.phymed.2012.03.005
Duan M, Ulibarri J, Liu KJ, Mao P. Role of Nucleotide Excision Repair in Cisplatin Resistance. Int J Mol Sci. 2020;21(23)
Gentile F, Tuszynski JA, Barakat KH. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy. J Mol Graph Model. 2016;65:71–82.
pubmed: 26939044
doi: 10.1016/j.jmgm.2016.02.010
Li W, Jie Z, Li Z, Liu Y, Gan Q, Mao Y, Wang X. ERCC1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines. Mol Med Rep. 2014;9(6):2423–8.
pubmed: 24699918
doi: 10.3892/mmr.2014.2112
Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med. 2016;22(2):128–34.
pubmed: 26845405
pmcid: 4918227
doi: 10.1038/nm.4036
Li Y, Gan Y, Liu J, Li J, Zhou Z, Tian R, Sun R, et al. Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer. Signal Transduct Target Ther. 2022;7(1):87.
pubmed: 35351858
pmcid: 8964798
doi: 10.1038/s41392-022-00902-6
Bai Y, Zhang Z, Cheng L, Wang R, Chen X, Kong Y, Feng F, et al. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer. J Biol Chem. 2019;294(25):9911–23.
pubmed: 31085587
pmcid: 6597805
doi: 10.1074/jbc.RA119.008152
Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13(1):104.
pubmed: 32723346
pmcid: 7385862
doi: 10.1186/s13045-020-00937-8
Gulati N, Béguelin W, Giulino-Roth L. Enhancer of zeste homolog 2 (EZH2) inhibitors. Leuk Lymphoma. 2018;59(7):1574–85.
pubmed: 29473431
pmcid: 6659997
doi: 10.1080/10428194.2018.1430795
Zhou W, Wang J, Man WY, Zhang QW, Xu WG. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells. Asian Pac J Cancer Prev. 2015;16(6):2425–30.
pubmed: 25824776
doi: 10.7314/APJCP.2015.16.6.2425
Rajput S, Puvvada N, Kumar BN, Sarkar S, Konar S, Bharti R, Dey G, et al. Overcoming Akt induced therapeutic resistance in breast cancer through siRNA and thymoquinone encapsulated multilamellar gold niosomes. Mol Pharm. 2015;12(12):4214–25.
pubmed: 26505213
doi: 10.1021/acs.molpharmaceut.5b00692
Zhang J, Wu X, Huang L. ZNF574 promotes ovarian cancer cell proliferation and migration through regulating AKT and AMPK signaling pathways. Ann Clin Lab Sci. 2022;52(4):611–20.
pubmed: 36197766
Peng S, Lu Y, Li P, Liu P, Shi X, Liu C, Zhang Y, et al. The short interference RNA (siRNA) targeting NMUR2 relieves nociception in a bone cancer pain model of rat through PKC-ERK and PI3K-AKT pathways. Biochem Biophys Res Commun. 2019;512(3):616–22.
pubmed: 30914203
doi: 10.1016/j.bbrc.2019.03.067
Ahn K, O YM, Ji YG, Cho HJ, Lee DH. Synergistic anti-cancer effects of AKT and SRC inhibition in human pancreatic cancer cells. Yonsei Med J. 2018;59(6):727–35.
pubmed: 29978609
pmcid: 6037593
doi: 10.3349/ymj.2018.59.6.727
Almalki WH. Beyond the genome: lncRNAs as regulators of the PI3K/AKT pathway in lung cancer. Pathol Res Pract. 2023;251: 154852.
pubmed: 37837857
doi: 10.1016/j.prp.2023.154852
Zhou W, Fu X-Q, Liu J, Yu H-G. RNAi knockdown of the Akt1 gene increases the chemosensitivity of gastric cancer cells to cisplatin both in vitro and in vivo. Regul Pept. 2012;176(1):13–21.
pubmed: 22387880
doi: 10.1016/j.regpep.2012.02.003
Yu S, Yu Y, Zhao N, Cui J, Li W, Liu T. C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis. PLoS ONE. 2013;8(11): e79137.
pubmed: 24223894
pmcid: 3817069
doi: 10.1371/journal.pone.0079137
Yang J, Shu G, Chen T, Dong A, Dong C, Li W, Sun X, et al. ESM1 Interacts with c-Met to Promote Gastric Cancer Peritoneal Metastasis by Inducing Angiogenesis. Cancers (Basel). 2023;16(1).
Anestis A, Zoi I, Karamouzis MV. Current advances of targeting HGF/c-Met pathway in gastric cancer. Ann Transl Med. 2018;6(12):247.
pubmed: 30069449
pmcid: 6046293
doi: 10.21037/atm.2018.04.42
Marano L, Chiari R, Fabozzi A, De Vita F, Boccardi V, Roviello G, Petrioli R, et al. c-Met targeting in advanced gastric cancer: an open challenge. Cancer Lett. 2015;365(1):30–6.
pubmed: 26049023
doi: 10.1016/j.canlet.2015.05.028
Yang JR, Ling XL, Guan QL. RAP2A promotes apoptosis resistance of hepatocellular carcinoma cells via the mTOR pathway. Clin Exp Med. 2021;21(4):545–54.
pubmed: 34018090
doi: 10.1007/s10238-021-00723-x
Xiong Z, Li B, Wang W, Zeng X, Li B, Jian S, Wang L. MiR-140 targets RAP2A to enable the proliferation of insulin-treated ovarian granulosa cells. J Ovarian Res. 2020;13(1):13.
pubmed: 32024547
pmcid: 7003402
doi: 10.1186/s13048-020-0611-4
Liu JQ, Zhao LP, Liu SX, Sun W, Qi HY. Abnormal expression of Rap2A as a prognostic marker for human breast cancer. Eur Rev Med Pharmacol Sci. 2020;24(18):9541–8.
pubmed: 33015796
Ti G, Guo Z, Li L, Lv Y, Yang B, Wang J, Guo R, et al. miR-33a-5p targets RAP2A to mediate the sensitivity of gastric cancer cells to 5-FU. Dis Markers. 2022;2022:9701047.
pubmed: 36046374
pmcid: 9424005
doi: 10.1155/2022/9701047
Wu J, Du W, Wang X, Wei L, Pan Y, Wu X, Zhang J, et al. Ras-related protein Rap2c promotes the migration and invasion of human osteosarcoma cells. Oncol Lett. 2018;15(4):5352–8.
pubmed: 29552178
pmcid: 5840554
Zhang J, Wei Y, Min J, Wang Y, Yin L, Cao G, Shen H. Knockdown of RAP2A gene expression suppresses cisplatin resistance in gastric cancer cells. Oncol Lett. 2020;19(1):350–8.
pubmed: 31897147
Cheng H, Sharen G, Wang Z, Zhou J. LncRNA UCA1 enhances cisplatin resistance by regulating CYP1B1-mediated apoptosis via miR-513a-3p in human gastric cancer. Cancer Manag Res. 2021;13:367–77.
pubmed: 33469378
pmcid: 7813468
doi: 10.2147/CMAR.S277399
Fang Q, Chen X, Zhi X. Long non-coding RNA (LncRNA) urothelial carcinoma associated 1 (UCA1) increases multi-drug resistance of gastric cancer via downregulating miR-27b. Med Sci Monit. 2016;22:3506–13.
pubmed: 27694794
pmcid: 5051552
doi: 10.12659/MSM.900688
Wang B, Huang Z, Gao R, Zeng Z, Yang W, Sun Y, Wei W, et al. Expression of long noncoding RNA urothelial cancer associated 1 promotes cisplatin resistance in cervical cancer. Cancer Biother Radiopharm. 2017;32(3):101–10.
pubmed: 28414550
Wang H, Guan Z, He K, Qian J, Cao J, Teng L. LncRNA UCA1 in anti-cancer drug resistance. Oncotarget. 2017;8(38):64638–50.
pubmed: 28969100
pmcid: 5610032
doi: 10.18632/oncotarget.18344
Dai Q, Zhang T, Li C. LncRNA MALAT1 regulates the cell proliferation and cisplatin resistance in gastric cancer via PI3K/AKT pathway. Cancer Manag Res. 2020;12:1929–39.
pubmed: 32214850
pmcid: 7078812
doi: 10.2147/CMAR.S243796
Xi Z, Si J, Nan J. LncRNA MALAT1 potentiates autophagy-associated cisplatin resistance by regulating the microRNA-30b/autophagy-related gene 5 axis in gastric cancer. Int J Oncol. 2019;54(1):239–48.
pubmed: 30365113
Zhang YF, Li CS, Zhou Y, Lu XH. Propofol facilitates cisplatin sensitivity via lncRNA MALAT1/miR-30e/ATG5 axis through suppressing autophagy in gastric cancer. Life Sci. 2020;244: 117280.
pubmed: 31926239
doi: 10.1016/j.lfs.2020.117280
Dai Q, Zhang T, Pan J, Li C. LncRNA UCA1 promotes cisplatin resistance in gastric cancer via recruiting EZH2 and activating PI3K/AKT pathway. J Cancer. 2020;11(13):3882–92.
pubmed: 32328192
pmcid: 7171500
doi: 10.7150/jca.43446
Aliabadi P, Sadri M, Siri G, Ebrahimzadeh F, Yazdani Y, Gusarov AM, Kharkouei SA, et al. Restoration of miR-648 overcomes 5-FU-resistance through targeting ET-1 in gastric cancer cells in-vitro. Pathol Res Pract. 2022;239: 154139.
pubmed: 36191447
doi: 10.1016/j.prp.2022.154139
Wang X, Kan J, Han J, Zhang W, Bai L, Wu H. LncRNA SNHG16 functions as an oncogene by sponging MiR-135a and promotes JAK2/STAT3 signal pathway in gastric cancer. J Cancer. 2019;10(4):1013–22.
pubmed: 30854107
pmcid: 6400807
doi: 10.7150/jca.29527
Zhao JJ, Liu JJ, Zhang YY, Xia Y, Du H, Yan ZQ, Zhou CH, et al. SNHG16 lncRNAs are overexpressed and may be oncogenic in human gastric cancer by regulating cell cycle progression. Neoplasma. 2022;69(1):49–58.
pubmed: 34881626
doi: 10.4149/neo_2021_210518N680
Ding Y, Gao S, Zheng J, Chen X. Blocking lncRNA-SNHG16 sensitizes gastric cancer cells to 5-Fu through targeting the miR-506-3p-PTBP1-mediated glucose metabolism. Cancer Metab. 2022;10(1):20.
pubmed: 36447254
pmcid: 9707261
doi: 10.1186/s40170-022-00293-w
Christensen LL, True K, Hamilton MP, Nielsen MM, Damas ND, Damgaard CK, Ongen H, et al. SNHG16 is regulated by the Wnt pathway in colorectal cancer and affects genes involved in lipid metabolism. Mol Oncol. 2016;10(8):1266–82.
pubmed: 27396952
pmcid: 5423192
doi: 10.1016/j.molonc.2016.06.003
Wu W, Guo L, Liang Z, Liu Y, Yao Z. Lnc-SNHG16/miR-128 axis modulates malignant phenotype through WNT/β-catenin pathway in cervical cancer cells. J Cancer. 2020;11(8):2201–12.
pubmed: 32127947
pmcid: 7052928
doi: 10.7150/jca.40319
Long Noncoding RNA. SNHG16 silencing inhibits the aggressiveness of gastric cancer via upregulation of microRNA-628-3p and consequent decrease of NRP1 [Retraction]. Cancer Manag Res. 2021;13:7493–4.
doi: 10.2147/CMAR.S341062
Lian D, Amin B, Du D, Yan W. Enhanced expression of the long non-coding RNA SNHG16 contributes to gastric cancer progression and metastasis. Cancer Biomark. 2017;21(1):151–60.
pubmed: 29081409
doi: 10.3233/CBM-170462
Yan LR, Ding HX, Shen SX, Lu XD, Yuan Y, Xu Q. Pepsinogen C expression-related lncRNA/circRNA/mRNA profile and its co-mediated ceRNA network in gastric cancer. Funct Integr Genom. 2021;21(5–6):605–18.
doi: 10.1007/s10142-021-00803-x
Zhou C, Zhao J, Liu J, Wei S, Xia Y, Xia W, Bi Y, et al. LncRNA SNHG16 promotes epithelial- mesenchymal transition via down-regulation of DKK3 in gastric cancer. Cancer Biomark. 2019;26(4):393–401.
pubmed: 31561329
doi: 10.3233/CBM-190497
Chen ZY, Wang XY, Yang YM, Wu MH, Yang L, Jiang DT, Cai H, et al. LncRNA SNHG16 promotes colorectal cancer cell proliferation, migration, and epithelial-mesenchymal transition through miR-124-3p/MCP-1. Gene Ther. 2022;29(3–4):193–205.
pubmed: 32859986
doi: 10.1038/s41434-020-0176-2
Pang W, Zhai M, Wang Y, Li Z. Long noncoding RNA SNHG16 silencing inhibits the aggressiveness of gastric cancer via upregulation of microRNA-628-3p and consequent decrease of NRP1. Cancer Manag Res. 2019;11:7263–77.
pubmed: 31447585
pmcid: 6682761
doi: 10.2147/CMAR.S211856
Zhang L, Liang H, Zhang J, Yang Y, Ling X, Jiang H. Long non-coding RNA SNHG16 facilitates Esophageal cancer cell proliferation and self-renewal through the microRNA-802/PTCH1 axis. Curr Med Chem. 2022;29(39):6084–99.
pubmed: 35579168
doi: 10.2174/0929867329666220510090418
Hu J, Huang L, Ding Q, Lv J, Chen Z. Long noncoding RNA HAGLR sponges miR-338-3p to promote 5-Fu resistance in gastric cancer through targeting the LDHA-glycolysis pathway. Cell Biol Int. 2022;46(2):173–84.
pubmed: 34658120
doi: 10.1002/cbin.11714
Shi Y, Pan J, Hang C, Tan L, Hu L, Yan Z, Zhu J. The estrogen/miR-338-3p/ADAM17 axis enhances the viability of breast cancer cells via suppressing NK cell’s function. Environ Toxicol. 2023;38(7):1618–27.
pubmed: 37052432
doi: 10.1002/tox.23791
Tian W, Yang X, Yang H, Lv M, Sun X, Zhou B. Exosomal miR-338-3p suppresses non-small-cell lung cancer cells metastasis by inhibiting CHL1 through the MAPK signaling pathway. Cell Death Dis. 2021;12(11):1030.
pubmed: 34718336
pmcid: 8557210
doi: 10.1038/s41419-021-04314-2
Wan L, Han Q, Zhu B, Kong Z, Feng E. Circ-TFF1 facilitates breast cancer development via regulation of miR-338-3p/FGFR1 axis. Biochem Genet. 2022;60(1):315–35.
pubmed: 34219206
doi: 10.1007/s10528-021-10102-6
Zou T, Duan J, Liang J, Shi H, Zhen T, Li H, Zhang F, et al. miR-338-3p suppresses colorectal cancer proliferation and progression by inhibiting MACC1. Int J Clin Exp Pathol. 2018;11(4):2256–67.
pubmed: 31938338
pmcid: 6958210
Niu Q, Liu Z, Gao J, Wang Q. MiR-338-3p enhances ovarian cancer cell sensitivity to cisplatin by downregulating WNT2B. Yonsei Med J. 2019;60(12):1146–56.
pubmed: 31769245
pmcid: 6881712
doi: 10.3349/ymj.2019.60.12.1146
Wu Q, Chen P, Li J, Lin Z, Zhang Q, Kwok HF. Inhibition of bladder cancer growth with homoharringtonine by inactivating integrin α5/β1-FAK/Src axis: a novel strategy for drug application. Pharmacol Res. 2023;188: 106654.
pubmed: 36640858
doi: 10.1016/j.phrs.2023.106654
Patwardhan S, Mahadik P, Shetty O, Sen S. ECM stiffness-tuned exosomes drive breast cancer motility through thrombospondin-1. Biomaterials. 2021;279: 121185.
pubmed: 34808560
doi: 10.1016/j.biomaterials.2021.121185
Ungewiss C, Rizvi ZH, Roybal JD, Peng DH, Gold KA, Shin DH, Creighton CJ, et al. The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL. Sci Rep. 2016;6:18652.
pubmed: 26728244
pmcid: 4700473
doi: 10.1038/srep18652
Genna A, Alter J, Poletti M, Meirson T, Sneh T, Gendler M, Saleev N, et al. FAK family proteins regulate in vivo breast cancer metastasis via distinct mechanisms. bioRxiv. 2023.
Lv PC, Jiang AQ, Zhang WM, Zhu HL. FAK inhibitors in cancer, a patent review. Expert Opin Ther Pat. 2018;28(2):139–45.
pubmed: 29210300
doi: 10.1080/13543776.2018.1414183
Hou J, Tan Y, Su C, Wang T, Gao Z, Song D, Zhao J, et al. Inhibition of protein FAK enhances 5-FU chemosensitivity to gastric carcinoma via p53 signaling pathways. Comput Struct Biotechnol J. 2020;18:125–36.
pubmed: 31969973
doi: 10.1016/j.csbj.2019.12.010
Speth PA, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet. 1988;15(1):15–31.
pubmed: 3042244
doi: 10.2165/00003088-198815010-00002
Yang J, Jiang X, Chen Y, Teng L. EIF5A2 Promotes doxorubicin resistance in bladder cancer cells through the TGF-β signaling pathway. Discov Med. 2023;35(179):1167–76.
pubmed: 38058082
doi: 10.24976/Discov.Med.202335179.113
Fraix A, Conte C, Gazzano E, Riganti C, Quaglia F, Sortino S. Overcoming doxorubicin resistance with lipid-polymer hybrid nanoparticles photoreleasing nitric oxide. Mol Pharm. 2020;17(6):2135–44.
pubmed: 32286080
doi: 10.1021/acs.molpharmaceut.0c00290
Ashrafizadeh M, Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Raei M, Hushmandi K, et al. Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression. Carbohydr Polym. 2021;272: 118491.
pubmed: 34420747
doi: 10.1016/j.carbpol.2021.118491
Chegaev K, Riganti C, Rolando B, Lazzarato L, Gazzano E, Guglielmo S, Ghigo D, et al. Doxorubicin-antioxidant co-drugs. Bioorg Med Chem Lett. 2013;23(19):5307–10.
pubmed: 23973213
doi: 10.1016/j.bmcl.2013.07.070
Gan RH, Wei H, Xie J, Zheng DP, Luo EL, Huang XY, Xie J, et al. Notch1 regulates tongue cancer cells proliferation, apoptosis and invasion. Cell Cycle. 2018;17(2):216–24.
pubmed: 29117785
doi: 10.1080/15384101.2017.1395534
Gharaibeh L, Elmadany N, Alwosaibai K, Alshaer W. Notch1 in cancer therapy: possible clinical implications and challenges. Mol Pharmacol. 2020;98(5):559–76.
pubmed: 32913140
doi: 10.1124/molpharm.120.000006
Guo L, Zhang T, Xiong Y, Yang Y. Roles of NOTCH1 as a therapeutic target and a biomarker for lung cancer: controversies and perspectives. Dis Markers. 2015;2015: 520590.
pubmed: 26491213
pmcid: 4600509
doi: 10.1155/2015/520590
Katoh M, Katoh M. Precision medicine for human cancers with Notch signaling dysregulation (review). Int J Mol Med. 2020;45(2):279–97.
pubmed: 31894255
Qi J, Meng M, Liu J, Song X, Chen Y, Liu Y, Li X, et al. Lycorine inhibits pancreatic cancer cell growth and neovascularization by inducing Notch1 degradation and downregulating key vasculogenic genes. Biochem Pharmacol. 2023;217: 115833.
pubmed: 37769714
doi: 10.1016/j.bcp.2023.115833
Zhou W, Tan W, Huang X, Yu HG. Doxorubicin combined with Notch1-targeting siRNA for the treatment of gastric cancer. Oncol Lett. 2018;16(3):2805–12.
pubmed: 30127866
pmcid: 6096196
Adhikari BR, Yoshida K, Paudel D, Morikawa T, Uehara O, Sato J, Muthumala M, et al. Aberrant expression of DUSP4 is a specific phenomenon in betel quid-related oral cancer. Med Mol Morphol. 2021;54(2):79–86.
pubmed: 32951127
doi: 10.1007/s00795-020-00265-3
Low HB, Zhang Y. Regulatory roles of MAPK Phosphatases in cancer. Immune Netw. 2016;16(2):85–98.
pubmed: 27162525
pmcid: 4853501
doi: 10.4110/in.2016.16.2.85
Ma B, Shi R, Yang S, Zhou L, Qu N, Liao T, Wang Y, et al. DUSP4/MKP2 overexpression is associated with BRAF(V600E) mutation and aggressive behavior of papillary thyroid cancer. Onco Targets Ther. 2016;9:2255–63.
pubmed: 27143921
pmcid: 4844429
Saigusa S, Inoue Y, Tanaka K, Toiyama Y, Okugawa Y, Shimura T, Hiro J, et al. Decreased expression of DUSP4 is associated with liver and lung metastases in colorectal cancer. Med Oncol. 2013;30(3):620.
pubmed: 23749251
doi: 10.1007/s12032-013-0620-x
Wang X, Chi W, Ma Y, Zhang Q, Xue J, Shao ZM, Xiu B, et al. DUSP4 enhances therapeutic sensitivity in HER2-positive breast cancer by inhibiting the G6PD pathway and ROS metabolism by interacting with ALDOB. Transl Oncol. 2024;46: 102016.
pubmed: 38843658
pmcid: 11214528
doi: 10.1016/j.tranon.2024.102016
Aughton K, Sabat-Pospiech D, Barlow S, Coupland SE, Kalirai H. Investigating the Role of DUSP4 in Uveal Melanoma. Transl Vis Sci Technol. 2022;11(12):13.
pubmed: 36576731
pmcid: 9804032
doi: 10.1167/tvst.11.12.13
Bang S, Jee S, Kim H, Jang K, Park H, Myung JK, Choi D, et al. Low DUSP4 expression is associated with aggressive phenotypes and poor prognosis in gastric cancer. In Vivo. 2021;35(1):131–40.
pubmed: 33402458
pmcid: 7880801
doi: 10.21873/invivo.12240
Huang S, Ma Z, Zhou Q, Wang A, Gong Y, Li Z, Wang S, et al. Genome-wide CRISPR/Cas9 library screening identified that DUSP4 deficiency induces lenvatinib resistance in hepatocellular carcinoma. Int J Biol Sci. 2022;18(11):4357–71.
pubmed: 35864956
pmcid: 9295068
doi: 10.7150/ijbs.69969
Xu W, Chen B, Ke D, Chen X. DUSP4 directly deubiquitinates and stabilizes Smad4 protein, promoting proliferation and metastasis of colorectal cancer cells. Aging (Albany NY). 2020;12(17):17634–46.
pubmed: 32897241
doi: 10.18632/aging.103823
Xu W, Nie C, Chen X. DUSP4 inhibits autophagic cell death and apoptosis in colorectal cancer by regulating BCL2-Beclin1/Bax signaling. Mol Biol Rep. 2023;50(4):3229–39.
pubmed: 36705792
doi: 10.1007/s11033-023-08270-2
Zhou L, Yao N, Yang L, Liu K, Qiao Y, Huang C, Du R, et al. DUSP4 promotes esophageal squamous cell carcinoma progression by dephosphorylating HSP90β. Cell Rep. 2023;42(5): 112445.
pubmed: 37141098
doi: 10.1016/j.celrep.2023.112445
Kang X, Li M, Zhu H, Lu X, Miao J, Du S, Xia X, et al. DUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transition. Oncotarget. 2017;8(55):94028–39.
pubmed: 29212207
pmcid: 5706853
doi: 10.18632/oncotarget.21522
Yang C, Zhu S, Feng W, Chen X. Calponin 3 suppresses proliferation, migration and invasion of non-small cell lung cancer cells. Oncol Lett. 2021;22(2):634.
pubmed: 34267826
pmcid: 8258620
doi: 10.3892/ol.2021.12895
Xia L, Yue Y, Li M, Zhang YN, Zhao L, Lu W, Wang X, et al. CNN3 acts as a potential oncogene in cervical cancer by affecting RPLP1 mRNA expression. Sci Rep. 2020;10(1):2427.
pubmed: 32051425
pmcid: 7016181
doi: 10.1038/s41598-020-58947-y
Xie Y, Ding W, Xiang Y, Wang X, Yang J. Calponin 3 acts as a potential diagnostic and prognostic marker and promotes glioma cell proliferation, migration, and invasion. World Neurosurg. 2022;165:e721–31.
pubmed: 35792226
doi: 10.1016/j.wneu.2022.06.136
Hong KS, Kim H, Kim SH, Kim M, Yoo J. Calponin 3 regulates cell invasion and doxorubicin resistance in gastric cancer. Gastroenterol Res Pract. 2019;2019:3024970.
pubmed: 30911294
pmcid: 6398029
doi: 10.1155/2019/3024970
Ou W, Lin L, Chen R, Xu Q, Zhou C. Circ_0081143 contributes to gastric cancer malignant development and doxorubicin resistance by elevating the expression of YES1 by targeting mziR-129-2-3p. Gut Liver. 2022;16(6):861–74.
pubmed: 35686503
pmcid: 9668504
doi: 10.5009/gnl210354
Wang S, Ping M, Song B, Guo Y, Li Y, Jia J. Exosomal CircPRRX1 enhances doxorubicin resistance in gastric cancer by regulating MiR-3064-5p/PTPN14 signaling. Yonsei Med J. 2020;61(9):750–61.
pubmed: 32882759
pmcid: 7471080
doi: 10.3349/ymj.2020.61.9.750
Herranz-Montoya I, Park S, Djouder N. A comprehensive analysis of prefoldins and their implication in cancer. iScience. 2021;24(11):103273.
pubmed: 34761191
pmcid: 8567396
doi: 10.1016/j.isci.2021.103273
Lipinski KA, Britschgi C, Schrader K, Christinat Y, Frischknecht L, Krek W. Colorectal cancer cells display chaperone dependency for the unconventional prefoldin URI1. Oncotarget. 2016;7(20):29635–47.
pubmed: 27105489
pmcid: 5045422
doi: 10.18632/oncotarget.8816
Chaves-Pérez A, Yilmaz M, Perna C, de la Rosa S, Djouder N. URI is required to maintain intestinal architecture during ionizing radiation. Science. 2019;364(6443).
Ding Z, Pan Y, Shang T, Jiang T, Lin Y, Yang C, Pang S, et al. URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers. Nat Commun. 2023;14(1):6269.
pubmed: 37805657
pmcid: 10560259
doi: 10.1038/s41467-023-41852-z
Gu J, Liang Y, Qiao L, Lu Y, Hu X, Luo D, Li N, et al. URI expression in cervical cancer cells is associated with higher invasion capacity and resistance to cisplatin. Am J Cancer Res. 2015;5(4):1353–67.
pubmed: 26101702
pmcid: 4473315
Bian H, Gu Y, Chen C, Chen J, Zhang F, Xu Z, Wang Q, et al. Silence of URI in gastric cancer cells promotes cisplatin-induced DNA damage and apoptosis. Am J Cancer Res. 2023;13(3):936–49.
pubmed: 37034221
pmcid: 10077030
Hu Y, Ma Z, He Y, Liu W, Su Y, Tang Z. LncRNA-SNHG1 contributes to gastric cancer cell proliferation by regulating DNMT1. Biochem Biophys Res Commun. 2017;491(4):926–31.
pubmed: 28754593
doi: 10.1016/j.bbrc.2017.07.137
Liu ZQ, He WF, Wu YJ, Zhao SL, Wang L, Ouyang YY, Tang SY. LncRNA SNHG1 promotes EMT process in gastric cancer cells through regulation of the miR-15b/DCLK1/Notch1 axis. BMC Gastroenterol. 2020;20(1):156.
pubmed: 32423385
pmcid: 7236477
doi: 10.1186/s12876-020-01272-5
Xu J, Xu Y, Ye G, Qiu J. LncRNA-SNHG1 promotes paclitaxel resistance of gastric cancer cells through modulating the miR-216b-5p-hexokianse 2 axis. J Chemother. 2023;35(6):527–38.
pubmed: 36548909
doi: 10.1080/1120009X.2022.2157618
Cosentino M, Forcina L, Zouhair M, Apa L, Genovese D, Boccia C, Rizzuto E, et al. Modelling three-dimensional cancer-associated cachexia and therapy: the molecular basis and therapeutic potential of interleukin-6 transignalling blockade. J Cachexia Sarcopenia Muscle. 2023;14(6):2550–68.
pubmed: 37727078
pmcid: 10751446
doi: 10.1002/jcsm.13329
Li S, Wei X, He J, Cao Q, Du D, Zhan X, Zeng Y, et al. The comprehensive landscape of miR-34a in cancer research. Cancer Metastasis Rev. 2021;40(3):925–48.
pubmed: 33959850
doi: 10.1007/s10555-021-09973-3
Pehlevan Özel H, Dinç T, Tiryaki RS, Keşküş AG, Konu Ö, Kayilioğlu SI, Coşkun F. Targeted MicroRNA profiling in gastric cancer with clinical assessement. Balkan J Med Genet. 2021;24(2):55–64.
pubmed: 36249523
doi: 10.2478/bjmg-2021-0022
Wu Y, Ni Z, Yan X, Dai X, Hu C, Zheng Y, He F, et al. Targeting the MIR34C-5p-ATG4B-autophagy axis enhances the sensitivity of cervical cancer cells to pirarubicin. Autophagy. 2016;12(7):1105–17.
pubmed: 27097054
pmcid: 4990997
doi: 10.1080/15548627.2016.1173798
Zheng H, Wang JJ, Yang XR, Yu YL. Upregulation of miR-34c after silencing E2F transcription factor 1 inhibits paclitaxel combined with cisplatin resistance in gastric cancer cells. World J Gastroenterol. 2020;26(5):499–513.
pubmed: 32089626
pmcid: 7015722
doi: 10.3748/wjg.v26.i5.499
Tseng JC, Chen HF, Wu KJ. A twist tale of cancer metastasis and tumor angiogenesis. Histol Histopathol. 2015;30(11):1283–94.
pubmed: 26084282
Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117(7):927–39.
pubmed: 15210113
doi: 10.1016/j.cell.2004.06.006
Husson O, Jones RL. Q-TWiST: What really matters to the cancer patient? Cancer. 2017;123(12):2200–2.
pubmed: 28294292
doi: 10.1002/cncr.30662
Khan MA, Chen HC, Zhang D, Fu J. Twist: a molecular target in cancer therapeutics. Tumour Biol. 2013;34(5):2497–506.
pubmed: 23873099
doi: 10.1007/s13277-013-1002-x
Sadrkhanloo M, Entezari M, Orouei S, Ghollasi M, Fathi N, Rezaei S, Hejazi ES, et al. STAT3-EMT axis in tumors: modulation of cancer metastasis, stemness and therapy response. Pharmacol Res. 2022;182: 106311.
pubmed: 35716914
doi: 10.1016/j.phrs.2022.106311
Kwon CH, Park HJ, Choi Y, Won YJ, Lee SJ, Park DY. TWIST mediates resistance to paclitaxel by regulating Akt and Bcl-2 expression in gastric cancer cells. Tumour Biol. 2017;39(10):1010428317722070.
pubmed: 28982309
doi: 10.1177/1010428317722070
Ke B, Guo XF, Li N, Wu LL, Li B, Zhang RP, Liang H. Clinical significance of Stathmin1 expression and epithelial-mesenchymal transition in curatively resected gastric cancer. Mol Clin Oncol. 2019;10(2):214–22.
pubmed: 30680197
Obayashi S, Horiguchi J, Higuchi T, Katayama A, Handa T, Altan B, Bai T, et al. Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients. Int J Oncol. 2017;51(3):781–90.
pubmed: 28766688
pmcid: 5564402
doi: 10.3892/ijo.2017.4085
Fang Z, Lin M, Chen S, Liu H, Zhu M, Hu Y, Han S, et al. E2F1 promotes cell cycle progression by stabilizing spindle fiber in colorectal cancer cells. Cell Mol Biol Lett. 2022;27(1):90.
pubmed: 36221072
pmcid: 9552509
doi: 10.1186/s11658-022-00392-y
Jeon TY, Han ME, Lee YW, Lee YS, Kim GH, Song GA, Hur GY, et al. Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer. 2010;102(4):710–8.
pubmed: 20087351
pmcid: 2837578
doi: 10.1038/sj.bjc.6605537
Fan K, Ni X, Shen S, Gong Z, Wang J, Xin Y, Zheng B, et al. Acetylation stabilizes stathmin1 and promotes its activity contributing to gallbladder cancer metastasis. Cell Death Discov. 2022;8(1):265.
pubmed: 35581193
pmcid: 9114396
doi: 10.1038/s41420-022-01051-z
Fan K, Zhang D, Li M, Shen S, Wang J, Ni X, Gong Z, et al. Carboxyl-terminal polypeptide fragment of MUC16 combing stathmin1 promotes gallbladder cancer cell migration and invasion. Med Oncol. 2020;37(12):114.
pubmed: 33196934
doi: 10.1007/s12032-020-01438-x
Alli E, Bash-Babula J, Yang J-M, Hait WN. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res. 2002;62(23):6864–9.
pubmed: 12460900
Bai T, Yokobori T, Altan B, Ide M, Mochiki E, Yanai M, Kimura A, et al. High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients. Br J Cancer. 2017;116(9):1177–85.
pubmed: 28334732
pmcid: 5418450
doi: 10.1038/bjc.2017.76
Rosenberg LH, Lafitte M, Quereda V, Grant W, Chen W, Bibian M, Noguchi Y, et al. Therapeutic targeting of casein kinase 1δ in breast cancer. Sci Transl Med. 2015;7(318):318ra202.
Shen C, Nayak A, Melendez RA, Wynn DT, Jackson J, Lee E, Ahmed Y, et al. Casein Kinase 1α as a Regulator of Wnt-Driven Cancer. Int J Mol Sci. 2020;21(16).
Tkachenko A, Onishchenko A. Casein kinase 1α mediates eryptosis: a review. Apoptosis. 2023;28(1–2):1–19.
pubmed: 36308624
doi: 10.1007/s10495-022-01776-3
Knippschild U, Wolff S, Giamas G, Brockschmidt C, Wittau M, Würl PU, Eismann T, et al. The role of the casein kinase 1 (CK1) family in different signaling pathways linked to cancer development. Onkologie. 2005;28(10):508–14.
pubmed: 16186692
Park SM, Miyamoto DK, Han GYQ, Chan M, Curnutt NM, Tran NL, Velleca A, et al. Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells. Cancer Cell. 2023;41(4):726-39.e11.
pubmed: 36898380
pmcid: 10466730
doi: 10.1016/j.ccell.2023.02.010
Guo Y, Zhu Z, Huang Z, Cui L, Yu W, Hong W, Zhou Z, et al. CK2-induced cooperation of HHEX with the YAP-TEAD4 complex promotes colorectal tumorigenesis. Nat Commun. 2022;13(1):4995.
pubmed: 36008411
pmcid: 9411202
doi: 10.1038/s41467-022-32674-6
Hanif IM, Hanif IM, Shazib MA, Ahmad KA, Pervaiz S. Casein Kinase II: an attractive target for anti-cancer drug design. Int J Biochem Cell Biol. 2010;42(10):1602–5.
pubmed: 20558317
doi: 10.1016/j.biocel.2010.06.010
Jiang S, Zhang M, Sun J, Yang X. Casein kinase 1α: biological mechanisms and theranostic potential. Cell Commun Signal. 2018;16(1):23.
pubmed: 29793495
pmcid: 5968562
doi: 10.1186/s12964-018-0236-z
Kim HJ, Han YS, Lee JH, Lee SH. Casein Kinase 2α Enhances 5-Fluorouracil Resistance in Colorectal Cancer Cells by Inhibiting Endoplasmic Reticulum Stress. Anticancer Res. 2020;40(3):1419–26.
pubmed: 32132038
doi: 10.21873/anticanres.14083
Jung M, Park KH, Kim HM, Kim TS, Zhang X, Park S-M, Beom S-H, et al. Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer. Gastric Cancer. 2019;22(6):1153–63.
pubmed: 31098863
doi: 10.1007/s10120-019-00971-7
Kang W, Tong JH, Chan AW, Cheng AS, Yu J, To K. MCM7 serves as a prognostic marker in diffuse-type gastric adenocarcinoma and siRNA-mediated knockdown suppresses its oncogenic function. Oncol Rep. 2014;31(5):2071–8.
pubmed: 24647462
doi: 10.3892/or.2014.3094
Liu Z, Shen L, Xu L, Sun X, Zhou J, Wu S. Down-regulation of β-1, 3-N-acetylglucosaminyltransferase-8 by siRNA inhibits the growth of human gastric cancer. Mol Med Rep. 2011;4(3):497–503.
pubmed: 21468598
Gencer S, Cebeci A, Irmak-Yazicioglu MB. Silencing of the MMP-3 gene by siRNA transfection in gastric cancer AGS cells. J GastrointestLiver Dis. 2011;20(1)
Sun H-W, Wu C, Tan H-Y, Wang Q-S. Combination DLL4 with Jagged1-siRNA can enhance inhibition of the proliferation and invasiveness activity of human gastric carcinoma by Notch1/VEGF pathway. Hepato Gastroenterol. 2012;59(115):924–9.
Yan K, He L-J, Cheng W, Ji Z-Z, Zhao B-X, Hui X-L, Cao S-S, et al. Inhibiting gastric cancer-associated angiogenesis by CIAPIN1 siRNA. Cancer Biol Ther. 2009;8(11):1058–63.
pubmed: 19502810
doi: 10.4161/cbt.8.11.8795
Chivu-Economescu M, Dragu DL, Necula LG, Matei L, Enciu AM, Bleotu C, Diaconu CC. Knockdown of KRT17 by siRNA induces antitumoral effects on gastric cancer cells. Gastric Cancer. 2017;20:948–59.
pubmed: 28299464
doi: 10.1007/s10120-017-0712-y
Sun Y, Guo Bf Xu, Lb ZJ, Zw L, Liang H, Wen N, et al. Stat3-siRNA inhibits the growth of gastric cancer in vitro and in vivo. Cell Biochem Funct. 2015;33(7):495–502.
pubmed: 26486443
doi: 10.1002/cbf.3148
Chan MWY, Wong CYP, Cheng ASL, Chan VYW, Chan KK, To KF, Chan FKL, et al. Targeted inhibition of COX-2 expression by RNA interference suppresses tumor growth and potentiates chemosensitivity to cisplatin in human gastric cancer cells. Oncol Rep. 2007;18(6):1557–62.
pubmed: 17982644
Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299–309.
pubmed: 31723286
pmcid: 8008476
doi: 10.1038/s41586-019-1730-1
Chen F, Zhuang M, Zhong C, Peng J, Wang X, Li J, Chen Z, et al. Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway. Oncol Rep. 2015;33(1):457–63.
pubmed: 25333894
doi: 10.3892/or.2014.3550